Vor Biopharma shares surged over 40% in premarket trading after JPMorgan initiated coverage with an Overweight rating and a $43 price target. The firm cited strong Phase 3 results for autoimmune drug telitacicept and called it highly de-risked. Retail sentiment turned extremely bullish, with message volume also spiking.